Johnson Fistel, PLLP is investigating potential claims on behalf of long-term shareholders of Ultragenyx Pharmaceutical Inc. against certain officers and directors for alleged breaches of fiduciary duty. Shareholders who have held Ultragenyx shares continuously since prior to August 3, 2023, may have standing to seek corporate governance reforms, the return of funds, and a court-approved incentive award at no cost. The investigation follows a previously filed securities class action alleging that Ultragenyx and certain executives made materially false and misleading statements about setrusumab and the Phase III ORBIT study in patients with osteogenesis imperfecta, creating a false impression of reliable information while minimizing the risk that the study would fail to achieve a statistically significant reduction in annualized fracture rate. The complaint further alleges that the company's optimism was misplaced because the threshold figures were based on Phase II results lacking a placebo control group.
UltragenyxInvestigation and securities class action alleging false statements about setrusumab and ORBIT study.